Santé

Company’s Cognitive Network Restoration Therapy (CNRT) technology aims to make meaningful cognitive recovery possible years after initial injury Targeting a brain hub involved in executive function, CNRT activates underperforming networks to reverse deficits and restore independence Groundbreaking therapeutic approach has the potential to transform chronic cognitive impairment care from rehabilitation to restoration EDINA, Minn., Sept. […]

Transaction positions Jaguar to advance the Laminar program and its differentiated approach to left atrial appendage closure for patients with non-valvular atrial fibrillation. SANTA ROSA, Calif., Sept. 11, 2026 /PRNewswire/ — Jaguar LAA, Inc. (“Jaguar”), a privately held medical device company, today announced the acquisition of assets related to the Laminar program, focused on addressing the

Listen to the full podcast here.

A recovering IPO market, surging mergers and acquisitions fuel more biotech venture deals. Read the full article here.

The rise of Chinese biotech and promise of AI are suddenly scrambling the industry’s playbook Read the full article here.  

Read the full article here.

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape. The COVID-19 pandemic may have come and gone, but its effects on the biotech industry have stretched on for years. Now, after half a decade of stress for smaller drugmakers, some venture capital investors are

Over the course of the 20th century, the first generations of pioneering drug developers found success initially through chance discoveries in nature, then by mining small industrial chemical libraries, and finally by deliberately designing chemical compounds for specific targets. Drug developers began defining “ideal” drug properties –design criteria later formalized as Lipinski’s “Rule of 5”

Venture capitalists focused on health are struggling to entice skeptical investors—but a handful are succeeding   Read the full article here.

 Firm exceeds $300 million target with Fund V; expands its base of limited partners; announces promotions of Dennis McWilliams and Omar Khalil to Managing Directors  Austin, TX – February 2, 2026 – Santé Ventures, a leading early-stage healthcare and life sciences investment firm, today announced the close of its fifth fund with $330 million in

Read the full article here.

Promotion and team expansion highlight continued momentum for the firm and reinforce support for breakthrough innovations in biotechnology AUSTIN, Texas, Sept. 23, 2025 /PRNewswire/ — Santé Ventures, (Santé), an early-stage healthcare and life sciences investment firm, has announced the promotion of Michael Gutbrod, PhD to Principal and the addition of Alana Horowitz, PhD as Senior Associate. Gutbrod joined Santé in

Learn more about how Michael Gutbrod, Senior Associate at Santé, and others are advancing cancer research funding in 2026 here.

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver linings exist, particularly for private companies. “You’ve got a market industry that is already facing a lot of challenges,” Omar Khalil, managing director at early-stage investor Santé Ventures, recently told Fierce Biotech. “And then

Read the full article here.

We’ve seen how transformative innovation can be when supported by focused investment. But if we want to continue advancing healthcare in meaningful ways, we must expand our lens and invest in the spaces that have been left behind. Healthcare innovation has taken remarkable strides in recent years. Breakthroughs in areas like structural heart, electrophysiology (EP),

Biotech companies with little runway left are trying to position themselves as attractive takeover targets to Big Pharma. Full article on Axios here.  

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels. A case can be made that metabolic medicine was the theme of the life sciences industry in

In recent years, a considerable amount of industry discussion has suggested that the pharmaceutical industry should move away from its traditional “blockbuster” drug model and lean towards one with a more personalized approach, driven by advances in genomics and the success of precision oncology and rare disease therapies. Yet today, we’re witnessing a remarkable counter-trend.

Santé Ventures is one of the 2024 winners of Private Equity and Venture Capital Awards at Wealth & Finance. Click this link to learn more.